TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

SORBITOL 3% IN PLASTIC CONTAINER

SORBITOL
Gastroenterology Approved 1980-05-30
1
Indication
--
Phase 3 Trials
45
Years on Market

Details

Status
Prescription
First Approved
1980-05-30
Routes
IRRIGATION
Dosage Forms
SOLUTION

Companies

Active Ingredient: SORBITOL

SORBITOL 3% IN PLASTIC CONTAINER Approval History

Loading approval history...

What SORBITOL 3% IN PLASTIC CONTAINER Treats

4 indications

SORBITOL 3% IN PLASTIC CONTAINER is approved for 4 conditions since its original approval in 1980. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Irregular Bowel Movements
  • Pain
  • Weakness
  • Nausea
Source: FDA Label

Drugs Similar to SORBITOL 3% IN PLASTIC CONTAINER

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

SORBITOL 3.3% IN PLASTIC CONTAINER
SORBITOL
4 shared
B BRAUN
Shared indications:
Irregular Bowel MovementsPainWeakness +1 more
ACUVAIL
KETOROLAC TROMETHAMINE
1 shared
AbbVie
Shared indications:
Pain
AKYNZEO
NETUPITANT
1 shared
HELSINN HLTHCARE
Shared indications:
Nausea
ANTIVERT
MECLIZINE HYDROCHLORIDE
1 shared
CASPER PHARMA LLC
Shared indications:
Nausea
APREPITANT
APREPITANT
1 shared
GLENMARK SPECLT
Shared indications:
Nausea
BELBUCA
BUPRENORPHINE HYDROCHLORIDE
1 shared
BDSI
Shared indications:
Pain
BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE
BISMUTH SUBSALICYLATE
1 shared
AILEX PHARMS LLC
Shared indications:
Nausea
BUPRENORPHINE
BUPRENORPHINE
1 shared
WATSON LABS TEVA
Shared indications:
Pain
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
ASPIRIN
1 shared
STEVENS J
Shared indications:
Pain
BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE
1 shared
Hikma
Shared indications:
Pain
BUTORPHANOL TARTRATE PRESERVATIVE FREE
BUTORPHANOL TARTRATE
1 shared
Pfizer
Shared indications:
Pain
BUTRANS
BUPRENORPHINE
1 shared
PURDUE PHARMA LP
Shared indications:
Pain
BYQLOVI
CLOBETASOL PROPIONATE
1 shared
HARROW EYE
Shared indications:
Pain
CALDOLOR
IBUPROFEN
1 shared
CUMBERLAND PHARMS
Shared indications:
Pain
CATAFLAM
DICLOFENAC POTASSIUM
1 shared
AMICI PHARMA
Shared indications:
Pain
CINVANTI
APREPITANT
1 shared
HERON THERAPS INC
Shared indications:
Nausea
COMBOGESIC IV
ACETAMINOPHEN
1 shared
Hikma
Shared indications:
Pain
COMPRO
PROCHLORPERAZINE
1 shared
PADAGIS US
Shared indications:
Nausea
DICLOFENAC POTASSIUM
DICLOFENAC POTASSIUM
1 shared
INGENUS PHARMS LLC
Shared indications:
Pain
DIFLUNISAL
DIFLUNISAL
1 shared
Teva
Shared indications:
Pain
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

SORBITOL 3% IN PLASTIC CONTAINER FDA Label Details

Pro

Indications & Usage

HOMEOPATHIC INDICATIONS: For temporary relief of symptoms related to chemical toxicity such as sleep disturbances, head discomfort, irregular bowel habits, memory difficulties, pain and weakness, trembling, nausea.** **These statements are based upon homeopathic principles. They have not been reviewed by the Food and Drug Administration.

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.